Leave a Message
+86 21 52992719

About Us

Yinjia (Shanghai) Biosciences Co., Ltd. is an innovation-driven technology platform company dedicated to develop and manufacture various difficult-to-express proteins which are widely applied in drug discovery, bioscience and other major people's livelihood fields. A variety of high-quality, good stability and competitive price high-end protein raw materials that are comparable to international brands have been developed, along with a dozen of highly market-demanding detection kits and diagnostic products derived from our proprietary core raw materials. These offerings provide more alternative solutions to address unmet needs in the global life and health industry.
View More+
Products and Services

Product Catalog

To date, nearly more than three hundreds of high-end protein raw materials, along with a dozen of quality control and safety evaluation detection kits for therapeutic biologics have been developed and launched on the market. Our products cover biopharmaceutical fields such as new drug development (such as ADC), diagnostics, vaccines, cell therapy, as well as bioscience applications such as proteomics, organoid etc. We empower listed pharmaceutical enterprises, innovative biotech firms, leading diagnostic companies and university/research institutions, delivering high-performance alternatives comparable to imported products.

More
Product Catalog
Product Catalog
Science-driven · Innovation-led · Craftsmen of Proteins · Uniquely Empowered
News
Insights_Stay Updated
Yinjia Bio and Intelligent Biosystem Officially Sign Strategic Cooperation Agreement to Jointly Advance a New Paradigm of AI-Assisted Protein Synthesis with Automated High-Throughput Dry-Wet Closed Loop
Recently, Yinjia (Shanghai) Biosciences ("Yinjia Bio") and Intelligent Biosystem officially signed a strategic cooperation agreement in Shanghai.The n
Yinjia Bio was invited to attend the "Biomanufacturing" Institution Day, where its AI-driven protein innovation attracted great attention from investors.
In early April 2026, against the backdrop of the "15th Five-Year Plan" designating biomanufacturing as a core future industry track, Hangzhou Yuhuangs
Honored Again! Yinjia Bio Named Among CHC-CITIC Securities' "Top 50 Most Investable Healthcare Companies 2024"
On May 15, 2025, the "2024 China Healthcare Industry Investment and Financing Honor Roll" was officially announced. Yinjia Bio was recognized on the "2024 Top 50 Most Investable Healthcare Companies" list for its innovative R&D capabilities, forward-looking strategic planning, and industry-leading practices.
YinJia Bio has joined hands with BioGeometry to forge a strategic partnership, propelling "Protein Artisan" to a new height of digital intelligence.
On May 31, 2024, Yinjia (Shanghai) Biomedical Technology Co., Ltd. (referred to as "Yinjia Bio") and Beijing BioGeometry Biotechnology Co., Ltd. (refe
Yinjia Bio Selected for Future Healthcare 100, Injecting New Vitality into the Global Pharmaceutical Industry
On May 6, the 7th Future Healthcare 100 Summit, co-organized by Shanghai Zhangjiang Group and VB100, was held. Yinjia (Shanghai) Biomedical Technology
Yinjia Bio Secures Nearly RMB 100 Million in Series A Financing to Accelerate Development of Novel Synthetic Biology Platform for Protein Synthesis
Yinjia (Shanghai) Biosciences (“Yinjia Bio”) recently closed its Series A financing round worth nearly RMB 100 million. The round was led by CMB Inter
  • 0 +
    Established in 2020
  • 0 +
    Nationwide Service Network
  • 0 +
    Patents Granted
  • 0 +
    Partners
  • 0 +
    Reagent Products
  • 0 +
    Core Strategic Partners